Boston Sci Q2 Revenue Up 23 Percent

Core Insights - Boston Scientific reported strong second-quarter 2025 results, with revenue of $5.06 billion and adjusted EPS of $0.75, both exceeding Wall Street expectations and the company's own guidance [1][2][5] Financial Performance - Revenue increased by 22.8% year-over-year from $4.12 billion in Q2 2024 to $5.06 billion in Q2 2025 [2] - Adjusted EPS rose by 21.0% from $0.62 in Q2 2024 to $0.75 in Q2 2025 [2] - Net income attributable to stockholders was $797 million, up from $324 million in the same quarter last year [5] - Adjusted gross margin was 69.5%, slightly down from early 2025 levels due to tariff impacts [5][13] Segment Performance - The Cardiovascular segment generated $3.35 billion in revenue, a 26.8% increase year-over-year, driven by the adoption of WATCHMAN and FARAPULSE devices [6] - The MedSurg segment revenue rose to $1.72 billion, a 15.7% increase, with Urology group growth at 28.9% due to acquisitions [7][8] Regional Performance - U.S. sales grew by 30.7%, contributing significantly to overall revenue growth, while EMEA saw a modest 6.8% increase and Asia-Pacific grew by 18% [9] Strategic Focus - The company is concentrating on building category leadership, investing in R&D, entering adjacent medical fields through acquisitions, and strengthening global reach [4] - Recent acquisitions include Intera Oncology and SoniVie Ltd., enhancing capabilities in high-growth therapy areas [11] Research and Development - R&D expenses increased to $526 million in Q2 2025, supporting new clinical trials and product development [12] Future Guidance - For Q3 2025, the company projects revenue growth of 17-19% and adjusted EPS of $0.70-0.72 [14] - For the full year, expected revenue growth is 18-19% with adjusted EPS of $2.95-2.99 [14]